Aquestive Therapeutics, Inc.
AQST· Nasdaq
AQSTAquestive Therapeutics, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0001628280-23-010180
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $10.68M | $11.08M | $7.15M | $16.42M |
| Net Income | -$12.35M | -$28.95M | -$20.37M | -$12.64M |
| EPS Diluted | — | — | -$0.60 | -$0.48 |
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
